Insights

Axinn Viewpoints

Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed

Pursuant to the Inflation Reduction Act (the “IRA”), the Secretary of Health and Human Services (“HHS”) and the Center for Medicare & Medicaid Services (“CMS”) have begun the annual process of negotiating with pharmaceutical companies regarding the price of certain drugs covered under Medicare Part D and Part B in an attempt to reduce drug prices.

Learn More

Awards & Recognitions

Axinn Announces Nominations for the Concurrences 2026 Antitrust Writing Awards

Axinn is pleased to announce that three written pieces authored by our lawyers have been nominated for the Concurrences 2026 Antitrust Writing Awards.

Learn More

Axinn Viewpoints

2025 Healthcare Antitrust Enforcement Wrap Up

On January 28, Axinn hosted a Healthcare Antitrust Year-In-Review CLE webinar, presented by counsel Carol Liu and Monica Smith, and associates Tasneem Chowdhury and Kaitlin Rittgers, and moderated by partner Lisl Dunlop, reviewing the most significant antitrust developments that shaped the healthcare industry in 2025 and providing practical insights into what those developments mean for the industry heading into 2026.

Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed

Pursuant to the Inflation Reduction Act (the “IRA”), the Secretary of Health and Human Services (“HHS”) and the Center for Medicare & Medicaid Services (“CMS”) have begun the annual process of negotiating with pharmaceutical companies regarding the price of certain drugs covered under Medicare Part D and Part B in an attempt to reduce drug prices.

Learn More

Axinn Viewpoints

2025 Healthcare Antitrust Enforcement Wrap Up

On January 28, Axinn hosted a Healthcare Antitrust Year-In-Review CLE webinar, presented by counsel Carol Liu and Monica Smith, and associates Tasneem Chowdhury and Kaitlin Rittgers, and moderated by partner Lisl Dunlop, reviewing the most significant antitrust developments that shaped the healthcare industry in 2025 and providing practical insights into what those developments mean for the industry heading into 2026.

Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed

Pursuant to the Inflation Reduction Act (the “IRA”), the Secretary of Health and Human Services (“HHS”) and the Center for Medicare & Medicaid Services (“CMS”) have begun the annual process of negotiating with pharmaceutical companies regarding the price of certain drugs covered under Medicare Part D and Part B in an attempt to reduce drug prices.

Learn More

Practices

Type

People

Most recent

13 results

March 25, 2025

Fintiv and the Resurgence of PTAB Discretionary Denials Involving the ITC

On March 24, 2025, the United States Patent and Tradmark Office ("USPTO") issued a new Memorandum providing guidance on discretionary...

Axinn Viewpoints

Intellectual Property

February 11, 2025

Federal Circuit Clarifies That “Quantitatively Small” Investments Can Establish Significant and Substantial Investment in Domestic Industry

On Friday, Feb. 7, 2025, the Federal Circuit issued a precedential opinion in Wuhan Healthgen Biotech. Corp. v. U.S. Int’l Trade Comm’n,...

Axinn Viewpoints

Intellectual Property

January 17, 2025

USITC Commissioner Series: Commissioner Schmidtlein is Stepping Down, Which Could Lead to More Tailored Exclusion Orders

This is an update to our 2024 USITC Commissioner Series. Read part one here, part two here, part three here, part four here, and part...

Axinn Viewpoints

Intellectual Property

January 10, 2025

Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation

On January 8, 2025, Administrative Law Judge (ALJ) Cameron Elliot issued a public version of the Initial Determination (ID) in Certain...

Axinn Viewpoints

Intellectual Property

January 2, 2025

Is 2025 the Year that the International Trade Commission Gives Guidance on Standard Essential Patents?

A big question when it comes to fair, reasonable and non-discriminatory (FRAND/RAND) defenses for standard essential patents (SEPs) is...

Axinn Viewpoints

Intellectual Property

May 15, 2024

Countdown to Deadline for Comment Submission to the ITC

Five days remain to submit comments to the ITC's Proposed Amendments to the Rules of Practice and Procedure for Section 337...

Axinn Viewpoints

Intellectual Property

May 3, 2024

USITC Commissioner Series: The Court's FRAND Dance May Soon Reach its Finale

This is part five of our USITC Commissioner Series. Read part one here, part two here, part three here and part four here. In prior posts...

Axinn Viewpoints

Intellectual Property

May 1, 2024

USITC Commissioner Series: What Divides the International Trade Commission?

At the International Trade Commission, a panel of up to six Commissioners is the gatekeeper of Section 337. Before the termination of any...

Axinn Viewpoints

Intellectual Property

April 22, 2024

USITC Commissioner Series: Top Dissenting Issues

This is part three of our USITC Commissioner Series. Read part one here, part two here, part four here and part five here. Following my...

Axinn Viewpoints

Intellectual Property

Axinn Announces Nominations for the Concurrences 2026 Antitrust Writing Awards

Insights

13 results

Events